Figure S6 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients

Abstract

<p>Figure S6 Figure S6. (A) Barplot showing the number of patients with at least one mutation in the MAPK, PI3K/AKT, or WNT pathways. (B-C) Kaplan-Meier estimates for progression-free survival (PFS) (B) and overall survival (OS) (C); patients were stratified according to the presence (activated; in blue) or absence (wild-type; in red) of somatic mutations in genes involved in the MAPK/PI3K/AKT pathways. (D) Kaplan-Meier estimates for PFS; patients were stratified according to the presence (activated; in blue) or absence (wild-type; in red) of mutations in genes involved in the WNT pathway. (E) Cumulative barplot showing the number of patients with mutations in the HR, NER, BER, POL, MMR, and NHEJ pathways: somatic mutations are in black, germline mutations are in white. (F) Boxplots representing the tumour mutational burden (TMB) per Mb for patients with altered genes involved in DNA repair pathways (altered; grey) or without altered genes in DNA repair pathways (wild-type; black), respectively. (G-H) Kaplan-Meier estimates for OS; patients were stratified according to the presence of somatic mutations (G) and pooled somatic and constitutional mutations (H) in genes involved in DNA repair pathways: wild-type (in red) and altered (in blue). (I) Kaplan-Meier estimates for OS; patients were stratified according to the DNA repair pathway state: single hit (only one mutation; in red) or double hit (in blue), which is at least two mutations or one mutation and one loss of heterozygosity. Only patients with at least one mutation in the DNA repair pathway were retained in this analysis. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; ns: not significant.</p>